These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17541591)

  • 1. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
    Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
    Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
    Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
    Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
    Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
    Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors.
    Delord JP; Puozzo C; Lefresne F; Bugat R
    Anticancer Res; 2009 Feb; 29(2):553-60. PubMed ID: 19331202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
    Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
    Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.
    Briasoulis E; Pappas P; Puozzo C; Tolis C; Fountzilas G; Dafni U; Marselos M; Pavlidis N
    Clin Cancer Res; 2009 Oct; 15(20):6454-61. PubMed ID: 19808873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
    Press RR; Buckle T; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
    Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of food on the pharmacokinetic profile of oral vinorelbine.
    Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
    Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can similar oral blood exposures between studies result in a different bioavailability?
    Puozzo C
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):838-41. PubMed ID: 16557414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.